4DMedical completes oversubscribed $8.4m SPP

25 March 2025

Highlights

- 4DMedical has completed a Securities Purchase Plan ("**SPP**") which follows its $5.5m Placement announced to ASX on 21 February 2025 ("**Placement**")
- The Company received valid applications for $8.4m worth of shares under the SPP. In recognition of the long-term support of its investors, the Board has exercised its discretion under the terms of the SPP and determined not to scale back applications
- Total proceeds of $13.9m (before costs) from the Placement and SPP will be used for general working capital as the Company accelerates the commercialisation of its functional and structural lung diagnostics portfolio, and drives towards FDA submission of its revolutionary ventilation and perfusion technology, CT:VQ™
- Funds raised leave the Company with a cash balance of approximately $29.1m after costs as at 31 December 2024 on a proforma basis

Melbourne, Australia, 25 March 2025: Respiratory imaging technology company, 4DMedical Limited (ASX:4DX, "**4DMedical**" or the "**Company**") is pleased to announce the successful completion of its SPP, details of which were announced to the ASX on 21 February 2025, and which closed at 5:00pm (AEDT) on Tuesday, 18 March 2025.

Strong support was received from Eligible Shareholders, with applications received totalling $8.4m. The SPP sought to raise $7.0m, and accordingly was oversubscribed by $1.4m. In recognition of the long-term support of its investors, the Board has exercised its discretion under the terms of the SPP and has determined not to scale back applications.

In accordance with the SPP terms, the issue price of the new fully paid ordinary shares ("**New Shares**") under the SPP is $0.36 per New Share, being the lower of $0.425 and the price calculated as a 2.5% discount to the VWAP of shares traded on the ASX during the five trading days up to the closing date of the SPP, rounded to the nearest half cent.

A total of 23,342,943 New Shares will be issued to SPP applicants at an issue price of $0.36 per New Share. The New Shares issued will represent 5.5% of 4DMedical's issued capital and will rank equally with existing shares on issue from their date of issue.

The New Shares issued under the SPP will be allotted on Tuesday, 25 March 2025 and are expected to commence trading on ASX on Wednesday, 26 March 2025.

The total funds raised, comprising the Placement ($5.5m) and SPP ($8.4m), amount to $13.9m (before costs) and will be used for general working capital as the Company accelerates the commercialisation of its functional and structural lung diagnostics portfolio, and drives towards FDA submission of its revolutionary ventilation and perfusion technology, CT:VQ™. Funds raised leave the Company with a cash balance of approximately $29.1m after costs as at 31 December 2024 on a proforma basis.

Bell Potter Securities Limited was sole Lead Manager and bookrunner to the Placement and SPP.

At its upcoming general meeting expected to be held on Thursday, 1 May 2025, the Company will seek Shareholder approval for the issue of 1 New Option for every 1 New Share issued under the SPP and

For personal use only

Melbourne
Level 7 Melbourne Connect
700 Swanston Street
Carlton VIC 3053
Tel: +61 (3) 9545 5940

Los Angeles
21255 Burbank Boulevard
Suite 120
Woodland Hills CA 91367
Tel: +1 (818) 403-8490

4DMedical Limited
ABN: 31 161 684 831
Email: info@4DMedical.com
www.4DMedical.com

For personal use only

Placement, whereby New Options validly exercised will entitle holders to receive 1 Piggyback Option and 1 New Share for every 1 New Option exercised.

4DMedical Founder and CEO Andreas Fouras said:

"I wish to personally thank our shareholders for supporting this SPP. Funds raised from the Placement and SPP, and expected funds to be raised from the exercise of two option tranches, will accelerate our commercialisation efforts, particularly in regard to our game-changing CT:VQ™ product. We're entering an exciting phase in 4DMedical's next stage of growth, and we look forward to delivering value for shareholders and world-class lung diagnostic tools for large scale access."

Key Dates for Capital Raising

Event	Timing (Melbourne time)
Announcement of results of the SPP	Tuesday, 25 March 2025
Allotment of New Shares under the SPP	Tuesday, 25 March 2025
Commencement of trading of New Shares under the SPP	Wednesday, 26 March 2025
EGM to approve issue of New Options (including relevant Piggyback Options) under Placement and SPP	Thursday, 1 May 2025
Issue of New Options under Placement and SPP (subject to EGM approval) Issue of Sub-Underwriter Options	Friday, 2 May 2025

–ENDS–

Authorised by the 4DMedical Board of Directors.

Contacts

Corporate
Investor Relations
investor.relations@4dmedical.com

Administration
Company Secretary
companysecretary@4dmedical.com

Media Enquiries
4Dmedia@4dmedical.com

About 4DMedical

4DMedical Limited (ASX:4DX) is a cutting-edge global medical technology company revolutionizing respiratory care. By harnessing advanced imaging and AI-powered solutions, 4DMedical delivers unprecedented insights into lung function, enabling earlier and more precise diagnoses of respiratory diseases.

©4DMedical Limited

For personal use only

At the heart of 4DMedical's innovation is its patented XV Technology®, a groundbreaking platform that dynamically quantifies ventilation throughout the lungs as patients breathe. This technology underpins the company's FDA-cleared XV Lung Ventilation Analysis Software (XV LVAS®) and its CT LVAS™, empowering physicians to detect and monitor regional airflow abnormalities with unparalleled sensitivity.

4DMedical's solutions integrate seamlessly into existing hospital infrastructure via its Software as a Service (SaaS) model, transforming routine imaging into powerful diagnostic tools.

In December 2023, 4DMedical expanded its leadership in medical imaging with the acquisition of **Imbio**, a pioneer in artificial intelligence solutions for chronic lung and cardiothoracic diseases. Imbio's AI-driven platforms enhance physician productivity, improve diagnostic precision, and support personalized care, aligning seamlessly with 4DMedical's mission to redefine respiratory healthcare.

To learn more, please visit www.4dmedical.com

©4DMedical Limited